The most innovative projects in the healthcare and biomedical sector were presented on December the 16th at the fourth edition of the Accelerator Meeting Point (AMP), organized by the Business Development and Innovation Area of the Biomedical Research Institute of Bellvitge (IDIBELL). The fourth edition of the AMP has counted on the participation of AIISEM, the Alliance for Health Innovation and Industrialization in the Mediterranean Axis, led by IDIBELL and driven by ISCIII, established by 9 research institutes and hospitals with the aim of build a unique portfolio of opportunities.
The meeting, this year held online, has enabled several IDIBELL entrepreneurs and has invited entities from the HealthTech/Biotech sector in order to present their projects to investors and pharmaceutical companies with the aim of finding funding.
This conference aims to offer investors and healthtech companies, national and international leaders in their sector, exclusive access to innovation projects at different stages of development.
In order to carry out the meeting in the best possible way, the organization has divided the conferences into two rooms. In each one, 10 projects have been displayed, according to their TRL (Technology Readiness Level). The “Investment” Room was predominated mainly by investors, and the “R+D Collaboration one”, was characterized by the presence of companies from the biotechnology and health sector.
Innovative projects were displayed, belonging to diverse fields such as oncology, regenerative medicine, mental health, metabolic diseases, infectious diseases (COVID-19) and sepsis. Proposed solutions include the development of new drugs and diagnostic methods, as well as the creation of medical devices based on digital therapeutic technologies.
At the end of the project presentations, investors and companies have the chance of selecting those proposals that roused the most interest in order to schedule B2B meetings.
The virtual meeting was attended by more than 50 companies in the sector, about 20 venture capital and investor companies, 15 pharmaceutical and biotechnology companies, and 15 sector agents, regulatory and consulting agencies, as a panel of experts with the aim of assessing the viability of projects and give their valuable feedback to entrepreneurs.
This way, and thanks to the strength of these new projects, the collaboration between researchers and companies is boosted, thereby positioning IDIBELL as a leader in innovation in Spain.